`
`
`
`
`For the Petitioner
`Lead counsel: James T. Carmichael, Reg. No. 45,306
`Backup counsel: Carol A. Spiegel, Reg. No. 68,033
`Carmichael IP, PLLC
`
`
`
`
`
`
`Paper No. __
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________________
`
`COALITION FOR AFFORDABLE DRUGS V LLC;
`HAYMAN CREDES MASTER FUND, L.P.;
`HAYMAN ORANGE FUND SPC – PORTFOLIO A;
`HAYMAN CAPITAL MASTER FUND, L.P.;
`HAYMAN CAPITAL MANAGEMENT FUND, L.P.;
`HAYMAN OFFSHORE MANAGEMENT, INC.;
`HAYMAN INVESTMENTS, LLC;
`NXN PARTNERS, LLC;
`IP NAVIGATION GROUP, LLC;
`J KYLE BASS, and ERICH SPANGENBERG,
`Petitioners,
`v.
`BIOGEN MA INC.,
`Patent Owner.
`____________________
`
`Case IPR2015-01993
`Patent 8,399,514 B2
`____________________
`
`PETITIONER REQUEST FOR ORAL ARGUMENT
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2015-01993
`Patent 8,399,514
`
`Pursuant to the Board’s Scheduling Order (Paper 34), the Notice of Joint
`
`Stipulation to Modify Due Dates 2-4 (Paper 44), and the Board’s Oral Arguments
`
`Order (Paper 56), Petitioner respectfully requests 20 minutes for oral argument in
`
`the trial currently scheduled on 30 November 2016. Pursuant to 37 C.F.R. §42.70,
`
`Petitioner specifies the following issues, without intent to waive consideration of
`
`any issue not requested, to be argued for this proceeding:
`
`1. Whether provisional application 60/888,921 (Ex. 1012)
`
`provides written descriptive support and enablement for the claims of U.S.
`
`Patent 8,399,514 (“the ‘514 patent”) as required by 35 U.S.C. §112, ¶1.
`
`2. Whether claims 1-6, 8-16 and 20 of the ‘514 patent are
`
`unpatentable under 35 U.S.C. §103(a) over Kappos 2006 (Ex. 1003A),
`
`ClinicalTrials (Ex. 1022), Joshi ‘999 (Ex. 1030) and/or ICH Guidelines (Ex.
`
`1004).
`
`3. Whether claim 7 of the ‘514 patent is unpatentable under 35
`
`U.S.C. §103(a) over Kappos 2006 (Ex. 1003A), ClinicalTrials (Ex. 1022),
`
`Joshi ‘999 (Ex. 1030), ICH Guidelines (Ex. 1004) and/or Joshi ‘992 (Ex.
`
`1036).
`
`4. Whether claims 17-19 of the ‘514 patent are unpatentable 35
`
`U.S.C. §103(a) over Kappos 2006 (Ex. 1003A), ClinicalTrials (Ex. 1022),
`
`
`
`2
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2015-01993
`Patent 8,399,514
`
`Joshi ‘999 (Ex. 1030), ICH Guidelines (Ex. 1004) and/or Begleiter (Ex.
`
`1027).
`
`5. Whether Biogen’s proffered secondary considerations show
`
`non-obviousness.
`
`6. Whether Biogen has established diligence throughout the
`
`critical period.
`
`Respectfully submitted,
`
`By: _/James T. Carmichael/____________
`James T. Carmichael, Reg. No. 45,306
`Carol A. Spiegel, Reg. No. 68,033
`Carmichael IP, PLLC
`8000 Towers Crescent Drive, Ste. 1350
`Tysons Corner, VA 22182
`(703) 646-9255
`
`Counsel for Petitioner
`IPR2015-01993
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: 26 October 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`
`Case No. IPR2015-01993
`Patent 8,399,514
`
`
`
`
`
`
`
`
`
`
`
`
`37 C.F.R. §42.6(e) CERTIFICATE OF SERVICE
`
`The undersigned certifies that a copy of the foregoing PETITIONER
`
`REQUEST FOR ORAL ARGUMENT was served on 26 October 2016, via
`
`electronic mail directed to counsel of record for the Patent Owner at the following:
`
`Michael J. Flibbert
`Maureen D. Queler
`Erin M. Sommers
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`michael.flibbert@finnegan.com
`maureen.queler@finnegan.com
`erin.sommers@finnegan.com
`
`Patent Owner has agreed to electronic service.
`
`
`
`Dated: 26 October 2016
`
`
`
`By: __/James T. Carmichael/__________
`James T. Carmichael, Reg. No. 45,306
`CARMICHAEL IP, PLLC
`8000 Towers Crescent Drive, Ste. 1350
`Tysons Corner, VA 22182
`(703) 646-9255
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`